Table 3.
Prior Therapies | N (%) |
---|---|
| |
Chemotherapy (gemcitabine+adriamycin, followed by carboplatinum plus paclitaxel) | 1 (3.57) |
| |
Interferon alfa | 4 (14.29) |
| |
TKI: | 15 (53.57) |
Sunitinib alone | 4 |
Sorafenib alone | 2 |
Sorafenib plus interferon | 2 |
Sequential sorafenib and sunitinib | 4 |
Bevacizumab plus erlotinib only | 2 |
Bevacizumab plus erlotinib followed by sunitinib | 1 |
| |
None | 10 (35.71) |
| |
Post Therapies | |
| |
TKI | 11 (39.29) |
| |
Other (interferon, temsirolimus, and thalidomide) | 3 (10.71) |